AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'

Amgen’s Lumakras and Mirati Therapeutics’ Krazati are “modestly effective” and have not led to the “dramatic advance for patients” that was initially thought possible when the once undruggable target was finally hacked, according to Jake Van Naarden, executive vice president at Lilly and CEO of Loxo@Lilly. Specifically, to make a real dent in the market, he said, KRAS inhibitors need to combine with standard-of-care PD-1 treatment—which in Loxo's opinion has not been smooth sailing for the first-to-market winners.